By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.
Sanofi has this week announced the UK launch of Suliqua™ (insulin glargine/lixisenatide) for the treatment of adults with type 2 diabetes. The drug is a once-daily, titratable, fixed-ratio ...
Abbott and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition, it has been ...
Sanofi has launched a new long-acting insulin glargine injection pen recommended for adults with type 1 or type 2 diabetes mellitus requiring at least 20 units of basal insulin per day. The ...
Global life sciences company Sanofi has pledged 10 million euros towards the rebuilding of Notre Dame after last week’s devastating fire. The Paris skyline was changed when a blaze tore ...
The deadline to nominate a healthcare professional for a major award is looming. Colleagues are being encouraged to submit an entry to the Quality in Care Diabetes (QiC) awards by Friday, July ...
Sanofi has presented results from the first head-to-head study comparing Toujeo® (insulin glargine 300 units/mL (Gla-300)) to insulin degludec. Gla-300 met primary endpoint in lowering blood ...
Healthcare professionals are being encouraged to enter a programme that celebrates excellence in diabetes care. The Quality in Care (QiC) Diabetes Awards aims to recognise the achievements of ...
Sanofi’s Toujeo® (insulin glargine 300 units/mL (Gla-300)) has demonstrated statistically significant improvements in HbA1c in people with type 1 diabetes at six months, according to ...
The insulin glargine Toujeo has been found to be just as effective as insulin degludec in the first head-to-head randomised clinical trial. The primary objective of the BRIGHT study was to ...
More than 340 sites have been taking part in a national campaign to raise awareness of hypoglycaemia. Hypo Awareness Week 2017 started on Monday, October 2, and runs to Sunday, October 8, with ...